

Resource Summary Report

Generated by [dkNET](#) on Aug 5, 2026

Anti-Histone H3.3 Antibody, K27M mutant

RRID:AB_2728728

Type: Antibody

Proper Citation

Millipore Cat# ABE419, RRID:AB_2728728

Antibody Information

URL: http://antibodyregistry.org/AB_2728728

Proper Citation: Millipore Cat# ABE419, RRID:AB_2728728

Target Antigen: Histone H3.3, K27M mutant

Host Organism: rabbit

Clonality: polyclonal

Comments: for use in western blotting (WB) & Chromatin immunoprecipitation (ChIP). original provider is Merck

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Anti-Histone H3.3 Antibody, K27M mutant

Description: This polyclonal targets Histone H3.3, K27M mutant

Target Organism: mouse, human

Antibody ID: AB_2728728

Vendor: Millipore

Catalog Number: ABE419

Record Creation Time: 20250819T233846+0000

Record Last Update: 20250820T055921+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Anti-Histone H3.3 Antibody, K27M mutant.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Esteve-Codina A, et al. (2021) RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP-negative Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(2), 645.

Dahl NA, et al. (2020) Super Elongation Complex as a Targetable Dependency in Diffuse Midline Glioma. Cell reports, 31(1), 107485.

Chaves C, et al. (2020) Characterization of the Blood-Brain Barrier Integrity and the Brain Transport of SN-38 in an Orthotopic Xenograft Rat Model of Diffuse Intrinsic Pontine Glioma. Pharmaceutics, 12(5).

Harutyunyan AS, et al. (2020) H3K27M in Gliomas Causes a One-Step Decrease in H3K27 Methylation and Reduced Spreading within the Constraints of H3K36 Methylation. Cell reports, 33(7), 108390.

Ryall S, et al. (2020) Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer cell, 37(4), 569.

Carrato C, et al. (2020) Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(24), 6600.

Chung C, et al. (2020) Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. Cancer cell, 38(3), 334.

Krug B, et al. (2019) Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas. Cancer cell, 35(5), 782.

Larson JD, et al. (2019) Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression. *Cancer cell*, 35(1), 140.

Anastas JN, et al. (2019) Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. *Cancer cell*, 36(5), 528.

Nagaraja S, et al. (2019) Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State. *Molecular cell*, 76(6), 965.

Kim GB, et al. (2019) Rapid Generation of Somatic Mouse Mosaics with Locus-Specific, Stably Integrated Transgenic Elements. *Cell*, 179(1), 251.

Mackay A, et al. (2018) Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. *Cancer cell*, 33(5), 829.

Fang D, et al. (2018) H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers. *eLife*, 7.